Immunotherapies

News

AC Immune's chief executive Dr Andrea Pfeifer

AC Immune says Parkinson's drug slows progression

AC Immune's active immunotherapy study backs up the alpha-synuclein hypothesis in Parkinson's disease, after disappointments in earlier trials.

News

First-in-class hay fever immunotherapy backed for NHS use

A once-daily tablet that can help people suffering from hay fever caused by tree pollen, Alk-Abelló's Itulazax, has been recommended for NHS use.

R&D

The future of fertility and the vaginal microbiome

As societies have modernised, fertility rates have declined substantially.

News

Takeda wagers up to $2.2bn on AC Immune Alzheimer’s shot

Takeda has made a strong play for a stake in the Alzheimer’s disease market, paying $100 million upfront for an option on AC Immune’s amyloid-targeting immunotherapy.

Oncology

The gut microbiome: the next breakthrough in cancer?

Ben Hargreaves discovers how research has emerged outlining how the gut microbiome plays a crucial role in patients’ response to cancer treatments.

Oncology

Partner Content

2nd Next Generation RNA Therapeutics Summit

Bringing Next Generation RNA Therapies to Patients Fast

AC Immune says Parkinson's drug slows progression

First-in-class hay fever immunotherapy backed for NHS use

The future of fertility and the vaginal microbiome

Takeda wagers up to $2.2bn on AC Immune Alzheimer’s shot

The gut microbiome: the next breakthrough in cancer?

2nd Next Generation RNA Therapeutics Summit

uniQure sets course to US filing for Huntington gene therapy

Discover a new era of healthcare panel engagement: Grounded ...

Immunotherapies

Editor's Picks